ES2042700T3 - Composiciones farmaceuticas con liberacion controlada, y metodo para su preparacion. - Google Patents

Composiciones farmaceuticas con liberacion controlada, y metodo para su preparacion.

Info

Publication number
ES2042700T3
ES2042700T3 ES88120153T ES88120153T ES2042700T3 ES 2042700 T3 ES2042700 T3 ES 2042700T3 ES 88120153 T ES88120153 T ES 88120153T ES 88120153 T ES88120153 T ES 88120153T ES 2042700 T3 ES2042700 T3 ES 2042700T3
Authority
ES
Spain
Prior art keywords
getting
pharmaceutical compositions
preparation
controlled release
lively
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES88120153T
Other languages
English (en)
Inventor
Mara Lucia Lovrecich
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vectorpharma International SpA
Original Assignee
Vectorpharma International SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vectorpharma International SpA filed Critical Vectorpharma International SpA
Application granted granted Critical
Publication of ES2042700T3 publication Critical patent/ES2042700T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/915—Therapeutic or pharmaceutical composition

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)

Abstract

COMPOSICIONES FARMACEUTICAS COMPRENDIENDO UN SOPORTE MICROPOROSO Y UNA SUBSTANCIA ACTIVA INCORPORADA EN ELLAS LA INCORPORACION DE DICHA SUBSTANCIA ACTIVA ESTANDO EFECTUADA AÑADIENDO EL SOPORTE MICROPOROSO O UNA SOLUCION DE LA SUBSTANCIA ACTIVA, AGITANDO LA MEZCLA OBTENIDA DURANTE AL MENOS 70 HORAS A TEMPERATURA AMBIENTE Y FINALMENTE EVAPORANDO EL SOLVENTE LENTAMENTE.
ES88120153T 1988-04-08 1988-12-02 Composiciones farmaceuticas con liberacion controlada, y metodo para su preparacion. Expired - Lifetime ES2042700T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT8820145A IT1216570B (it) 1988-04-08 1988-04-08 Composizione farmaceutiche a rilascio controllato e procedimento per la loro preparazione.

Publications (1)

Publication Number Publication Date
ES2042700T3 true ES2042700T3 (es) 1993-12-16

Family

ID=11164167

Family Applications (1)

Application Number Title Priority Date Filing Date
ES88120153T Expired - Lifetime ES2042700T3 (es) 1988-04-08 1988-12-02 Composiciones farmaceuticas con liberacion controlada, y metodo para su preparacion.

Country Status (6)

Country Link
US (1) US5008114A (es)
EP (1) EP0336014B1 (es)
AT (1) ATE77547T1 (es)
DE (1) DE3872382T2 (es)
ES (1) ES2042700T3 (es)
IT (1) IT1216570B (es)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5290570A (en) * 1989-05-30 1994-03-01 Purepac, Inc. Lotions containing liquid-loaded powder
FR2694701B1 (fr) * 1990-04-18 1996-01-19 Biagianti Irene Application des zeolithes naturelles a l'homme et a l'environnement.
IT1243745B (it) * 1990-10-17 1994-06-21 Vectorpharma Int Composizioni terapeutiche transdermali contenenti farmaco e/o agente promotore dell'assorbimento cutaneo supportato su particelle microporose e microsfere polimeriche e loro preparazione.
US5225204A (en) * 1991-11-05 1993-07-06 Chen Jivn Ren Stable dosage of levothyroxine sodium and process of production
US5409903A (en) * 1992-02-18 1995-04-25 Urecap Corporation Method and compositions for the treatment of H. pylori and dermatitis
US5298261A (en) * 1992-04-20 1994-03-29 Oregon Freeze Dry, Inc. Rapidly distintegrating tablet
AU4932493A (en) * 1992-09-25 1994-04-26 Dynagen, Inc. An immunobooster for delayed release of immunogen
ATE188375T1 (de) * 1992-11-17 2000-01-15 Yoshitomi Pharmaceutical Ein antipsychotikum enthaltende mikrokugel zur verzögerten freisetzung und verfahren für ihre herstellung
NZ262562A (en) * 1993-02-23 1996-04-26 Warner Lambert Co Preparation of solvent free pharmaceutical compositions
ATE288270T1 (de) 1993-11-19 2005-02-15 Janssen Pharmaceutica Nv Mikroverkapselte 1,2-benzazole
DE4416001C2 (de) * 1994-05-06 1997-12-11 Feinchemie Gmbh Sebnitz Komposite zur steuerbaren Wirkstoff-Freisetzung
WO1996025918A1 (en) * 1995-02-24 1996-08-29 Nanosystems L.L.C. Aerosols containing nanoparticle dispersions
DK0906243T4 (da) * 1996-05-29 2009-06-08 Delsitech Oy Oplöselige oxider til biologiske anvendelser
US6764690B2 (en) 1996-05-29 2004-07-20 Delsitech Oy Dissolvable oxides for biological applications
US7101575B2 (en) 1998-03-19 2006-09-05 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Production of nanocapsules and microcapsules by layer-wise polyelectrolyte self-assembly
US6524620B2 (en) 1998-07-20 2003-02-25 Andrx Pharmaceuticals, Inc. Diltiazem controlled release formulation and method of manufacture
SK10612001A3 (sk) * 1999-02-22 2002-02-05 Bioxid Oy Spôsob výroby riadene biodegradovateľných keramických vlákien z hydrosólu oxidu kremičitého
GB9904485D0 (en) * 1999-02-27 1999-04-21 Procter & Gamble Method for protecting and/or controlled release of active ingredient
WO2000077281A1 (en) * 1999-06-10 2000-12-21 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Encapsulation of crystals via multilayer coatings
US7108866B1 (en) 1999-12-10 2006-09-19 Biovall Laboratories International Srl Chronotherapeutic diltiazem formulations and the administration thereof
US20060153914A1 (en) * 1999-12-10 2006-07-13 Biovail Laboratories International S.R.L. Chronotherapeutic diltiazem formulations and the administration thereof
EP1269994A3 (en) * 2001-06-22 2003-02-12 Pfizer Products Inc. Pharmaceutical compositions comprising drug and concentration-enhancing polymers
JP4547148B2 (ja) * 2001-06-22 2010-09-22 ベンド・リサーチ・インコーポレーテッド 非晶質薬剤の吸着物の医薬組成物
WO2003063833A1 (en) 2002-02-01 2003-08-07 Pfizer Products Inc. Pharmaceutical compositions of amorphous dispersions of drugs and lipophilic microphase-forming materials
US20040132771A1 (en) * 2002-12-20 2004-07-08 Pfizer Inc Compositions of choleseteryl ester transfer protein inhibitors and HMG-CoA reductase inhibitors
MXPA06001417A (es) 2003-08-04 2006-05-15 Pfizer Prod Inc Composiciones farmaceuticas de adsorbatos de farmacos amorfos y materiales que forman microfases lipofilas.
US7387793B2 (en) 2003-11-14 2008-06-17 Eurand, Inc. Modified release dosage forms of skeletal muscle relaxants
MY142989A (en) * 2004-03-10 2011-02-14 Bayer Schering Pharma Ag Stabilised supersaturated solids of lipophilic drugs
DE102004013637A1 (de) 2004-03-19 2005-10-13 Capsulution Nanoscience Ag Verfahren zur Herstellung von CS-Partikeln und Mikrokapseln unter Verwendung poröser Template sowie CS-Partikel und Mikrokapseln
FI20070174A0 (fi) * 2007-02-28 2007-02-28 Delsitech Oy Menetelmä silikakoostumusten valmistamiseksi, silikakoostumukset ja niiden käytöt
ITMI20071930A1 (it) * 2007-10-05 2009-04-06 Sasol Italy S P A Composizioni farmaceutiche a base di zeoliti porose quali mezzi di rilascio di molecole farmacologicamente attive e relativo uso
PL2403482T3 (pl) 2009-03-04 2018-06-29 Emplicure Ab Preparat odporny na nadużywanie
PL2427177T3 (pl) 2009-05-08 2018-09-28 Emplicure Ab Kompozycja do przedłużonego podawania leku zawierająca geopolimerowy środek wiążący
WO2012032337A2 (en) 2010-09-07 2012-03-15 Orexo Ab A transdermal drug administration device
US9526701B2 (en) * 2011-12-20 2016-12-27 Keith R. Latham Sustained drug release and improved product stability using non-covalent particle coating methods
CN105050708A (zh) 2012-11-14 2015-11-11 格雷斯公司 含有生物活性材料与无序无机氧化物的组合物
KR20160137626A (ko) * 2014-03-31 2016-11-30 메사추세츠 인스티튜트 오브 테크놀로지 제약상 활성 종을 포함하는 화합물을 함유한 다공성 물질
GB201502073D0 (en) 2015-02-09 2015-03-25 Cubic Pharmaceuticals Ltd And Delta Pharmaceuticals Ltd HDEG technology
JP7672268B2 (ja) * 2020-04-22 2025-05-07 沢井製薬株式会社 コハク酸ソリフェナシン含有コーティング粒子及びそれを含む口腔内崩壊錠

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3923969A (en) * 1973-06-12 1975-12-02 Battelle Institut E V Carrier system for a drug with sustained release
US4013785A (en) * 1975-03-21 1977-03-22 Bristol-Myers Company Apap tablet containing fumed silica and process for manufacturing same
DE2845326C2 (de) * 1978-10-18 1985-05-23 Beiersdorf Ag, 2000 Hamburg Verwendung einer spezifischen mikrodispersen, amorphen, porösen Kieselsäure zur Herstellung von Digoxin enthaltenden Tabletten mit stark beschleunigter Wirkstoff-Freisetzung
US4834978A (en) * 1984-10-01 1989-05-30 Biotek, Inc. Method of transdermal drug delivery
GB8606468D0 (en) * 1986-03-15 1986-04-23 Sds Biotech Uk Ltd Therapeutic compositions
US4775535A (en) * 1986-04-04 1988-10-04 Hans Lowey Method of preparing controlled long-acting pharmaceutical formulations in unit dosage form having uniform and comparable bioavailability characteristics
JPS6327502A (ja) * 1986-07-22 1988-02-05 Agency Of Ind Science & Technol シクロデキストリン−シリカ複合体及びその製造方法

Also Published As

Publication number Publication date
EP0336014A1 (en) 1989-10-11
EP0336014B1 (en) 1992-06-24
DE3872382T2 (de) 1992-12-10
IT8820145A0 (it) 1988-04-08
DE3872382D1 (de) 1992-07-30
ATE77547T1 (de) 1992-07-15
US5008114A (en) 1991-04-16
IT1216570B (it) 1990-03-08

Similar Documents

Publication Publication Date Title
ES2059729T5 (es) Preparado farmaceutico de liberacion controlada y metodo para producir el mismo.
DE3872382D1 (de) Pharmazeutische zusammensetzungen mit verlaengerter wirkung und verfahren zu ihrer herstellung.
DE10075031I2 (de) Zusammensetzung zur kontrollierten Abgabe eines Wirkstoffs.
ES509647A0 (es) Procedimiento para preparar una polilactida.
ES2173142T3 (es) Dispositivo y procedimiento para la captura y recuperacion de celulas.
DE3583799D1 (de) Feste zubereitung mit langsamer freisetzung.
ES516375A0 (es) Procedimiento para la obtencion de una composicion a base de estireno para revestir alimentos y medicamentos.
HUT50624A (en) Process for producing pharmaceuical compositions with controlled release of active ingredient
DK0436370T3 (da) Farmaceutisk præparat til kontrolleret afgivelse og fremgangsmåde til fremstilling deraf
DE3585542D1 (de) Methoden zur herstellung biologisch aktiver membranen und ihre verwendungen.
DE69000881D1 (de) 2-propylvaleriansaeure enthaltende arzneizubereitung mit verzoegerter wirkstofffreigabe.
UA19303A (uk) Спосіб одержаhhя похідhих 2-аhіліhопіримідиhу
MX6223E (es) Procedimiento mejorado para la preparacion de provectiles balisticos que contienen una composicion biologicamente activa
IT1232827B (it) Proteine biologicamente attive, formulazioni che le contengono e metodo per prepararle ed applicarle
IT1230047B (it) Protesi vascolare contenente nella parete microcapsule inglobanti cellule produttrici di ormoni.
BR9607752A (pt) Formulação farmacêutica de microcápsula de liberação controlada, processo para sua preparação, e, processo de uso das microcápsulas
KR960016889A (ko) 뇌기능 개선제
DE3884517D1 (de) Biologisch aktive carbonsaeureester.
BR9305783A (pt) Processo para preparar grânulos dispersiveis em água e grânulos dispersíveis em água
ES546840A0 (es) Un procedimiento para preparar una sal de acido n-acetil- neuraminico
DE19475001I2 (de) Anthelminthische Wirkstoffkombinationen.
ES2016620B3 (es) Sistema para liberar medicamentos con bioaceptabilidad mejorada.
TR28970A (tr) Makrosiklik laktonlar, hazirlanmalarina mahsus usul ve zararlilarin kontrolünde kullanimlari.
DK585889D0 (da) Farmaceutisk praeparat
ES491307A0 (es) Un procedimiento para la preparacion de una composicion de liberacion controlada de un compuesto biologicamente activo para su administracion a un animal

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 336014

Country of ref document: ES